NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $236.75 -2.65 (-1.11%) As of 09/4/2026 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Quest Diagnostics Stock (NYSE:DGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$235.38▼$238.9250-Day Range$201.64▼$244.7852-Week Range$171.18▼$247.19Volume798,698 shsAverage Volume844,347 shsMarket Capitalization$26.13 billionP/E Ratio25.13Dividend Yield1.45%Price Target$235.31Consensus RatingModerate Buy Company Overview Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening. Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. Quest also offers specialized esoteric testing, employer and occupational health testing, clinical trial laboratory services and health information solutions designed to integrate lab data into provider and population health workflows. These capabilities are delivered through laboratory infrastructure, patient collection sites and digital tools that enable ordering, reporting and analytics. Quest primarily serves the United States healthcare market—providing testing and related services to physician practices, hospitals, payers, employers and governmental agencies—while maintaining capabilities that support international clinical trials and diagnostics initiatives. The company has operated for multiple decades and is structured with centralized laboratory operations, regional service locations and an executive leadership team responsible for strategic, clinical and operational oversight.AI Generated. May Contain Errors. Read More Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreDGX MarketRank™: Quest Diagnostics scored higher than 90% of companies evaluated by MarketBeat, and ranked 53rd out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 1 strong buy rating, 5 buy ratings, 7 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageQuest Diagnostics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.35% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 7.35% in the coming year, from $11.15 to $11.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 25.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 25.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.10.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.04% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 4.67.Change versus previous monthShort interest in Quest Diagnostics has recently decreased by 9.85%, indicating that investor sentiment is improving significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.45%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 36.52%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 28.74% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. News and Social Media4.6 / 5News Sentiment1.29 News SentimentQuest Diagnostics has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.Search Interest9 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,316,493.00 in company stock.Percentage Held by Insiders0.88% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGX Stock News HeadlinesQuest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGXSeptember 4 at 3:21 AM | finance.yahoo.comQuest Diagnostics (NYSE:DGX) SVP Michael Prevoznik Sells 22,677 Shares of StockSeptember 1, 2026 | insidertrades.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle. | Traders Agency (Ad)Quest Diagnostics stock: Is Wall Street bullish or bearish?August 26, 2026 | msn.comQuest Diagnostics to Speak at the Baird 2026 Global Healthcare ConferenceAugust 25, 2026 | prnewswire.comHumanity Brings Biological Age Analysis to the U.S. Through questhealth.comAugust 25, 2026 | prnewswire.comQuest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare ConferenceAugust 24, 2026 | prnewswire.comQuest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease PathologyAugust 24, 2026 | prnewswire.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $173.47 at the start of the year. Since then, DGX shares have increased by 36.5% and is now trading at $236.75. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) issued its earnings results on Thursday, July, 23rd. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.82 by $0.30. Quest Diagnostics's quarterly revenue was up 10.2% compared to the same quarter last year. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors authorized a share buyback plan on Tuesday, February 10th 2026, which authorizes the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board of directors believes its shares are undervalued. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Quest Diagnostics' top institutional investors include California State Teachers Retirement System (33.56%), BlackRock Inc. (8.40%), Bank of America Corp DE (1.75%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.85%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Record date for 7/22 Dividend7/08/2026Ex-Dividend for 7/22 Dividend7/08/2026Dividend Payable7/22/2026Last Earnings7/23/2026Today9/05/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/20262026 Global Healthcare Conference9/15/2026Record date for 10/21 Dividend10/06/2026Ex-Dividend for 10/21 Dividend10/06/2026Next Earnings (Estimated)10/20/2026Dividend Payable10/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DGX's financial health is in the Green zone, according to TradeSmith. DGX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees57,000Year Founded1967Price Target and Rating Average Price Target for Quest Diagnostics$235.31 High Price Target$260.00 Low Price Target$200.00 Potential Upside/Downside-0.6%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$9.42 Trailing P/E Ratio25.13 Forward P/E Ratio21.23 P/E Growth2.17Net Income$992 million Net Margins9.18% Pretax Margin12.15% Return on Equity16.01% Return on Assets7.27% Debt Debt-to-Equity Ratio0.72 Current Ratio1.59 Quick Ratio1.46 Sales & Book Value Annual Sales$11.04 billion Price / Sales2.37 Cash Flow$15.15 per share Price / Cash Flow15.63 Book Value$70.84 per share Price / Book3.34Miscellaneous Outstanding Shares110,370,000Free Float109,402,000Market Cap$26.13 billion OptionableOptionable Beta0.55 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:DGX) was last updated on 9/6/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DGX Stock Alerts